Upcoming webinar

Navigating MIBC management: Integrating ctDNA into clinical practice

Date: Monday, July 20, 2026
Time: 5:00 - 5:45 PM ET (45-minute webinar)
Registrants will receive a recording of the webinar approximately one week after the event.

Learn more about:

Join Michael Adashek, DO, medical oncologist, hematologist, and Director of GU Medical Oncology at Chesapeake Urology, for a live, case-based webinar designed for urologists.

This session will explore how ctDNA testing may provide additional insight across key MIBC decision points, including:
  • After TURBT and before cystectomy
  • During neoadjuvant therapy
  • After cystectomy and throughout surveillance
Dr. Adashek will review practical patient cases and discuss relevant clinical data, including IMvigor011 and NIAGARA, to help illustrate how ctDNA may support multidisciplinary MIBC management.

Register Now:

Please fill in the field above only if you have specific questions. Otherwise, leave it blank.

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.

Hear from our speaker:


Michael Adashek, DO
Michael Adashek, DO
Medical Oncologist and Hematologist
Director of GU Medical Oncology
Chesapeake Urology
Dr. Adashek is a medical oncologist, hematologist, and Director of GU Medical Oncology at Chesapeake Urology in Towson. He specializes in prostate, bladder, kidney, testicular, and penile cancers, as well as hematologic disorders.
Signatera™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved.
13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Do Not Share My Personal Information | Privacy Policy